iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $110.79 and last traded at $110.73, with a volume of 208,462 shares traded. The stock had previously closed at $110.46.
iShares U.S. Pharmaceuticals ETF Stock Performance
The firm has a fifty day simple moving average of $102.73 and a 200 day simple moving average of $95.49. The company has a market cap of $1.69 billion, a PE ratio of 17.75 and a beta of 0.47.
Institutional Investors Weigh In On iShares U.S. Pharmaceuticals ETF
A number of institutional investors have recently bought and sold shares of IHE. AdvisorNet Financial Inc purchased a new stake in shares of iShares U.S. Pharmaceuticals ETF during the 3rd quarter valued at $5,224,000. Tidal Investments LLC purchased a new position in shares of iShares U.S. Pharmaceuticals ETF in the 2nd quarter worth $3,716,000. Schuylkill Financial LLC purchased a new position in shares of iShares U.S. Pharmaceuticals ETF in the 2nd quarter worth $992,000. Bank of America Corp DE raised its position in shares of iShares U.S. Pharmaceuticals ETF by 2.8% in the 1st quarter. Bank of America Corp DE now owns 456,606 shares of the company’s stock worth $39,579,000 after buying an additional 12,565 shares during the period. Finally, Compass Financial Management LLC acquired a new position in iShares U.S. Pharmaceuticals ETF in the second quarter valued at $565,000.
iShares U.S. Pharmaceuticals ETF Company Profile
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Recommended Stories
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
- Why Apple Stock Looks Like a Safe Haven After the Midterms
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
